Genetic polymorphisms and expression of HLA-G and its receptors, KIR2DL4 and LILRB1, in non-small cell lung cancer

Tissue Antigens

Volumn 85, Issue 6, 2015, Pages 466-475

  Wisniewski A ^a   Kowal, A ^b   Wyrodek, E ^b   Nowak, I ^a   Majorczyk, E ^a,c   Wagner, M ^a   Pawlak Adamska, E ^a   Jankowska, R ^b   Slesak B ^d   Frydecka, I ^a   Kusnierczyk P ^a  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c OPOLE UNIVERSITY OF TECHNOLOGY   (Poland)

^d OPOLE MEDICAL SCHOOL   (Poland)

Author keywords

Genetics; Human leukocyte antigen G; Immunohistochemistry; KIR2DL4; LILRB1; Nonsmall cell lung cancer; Protein expression

Indexed keywords

HLA G ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL4; PROTEIN LILRB1; PROTEIN LILRB2; RECEPTOR PROTEIN; UNCLASSIFIED DRUG; IMMUNOGLOBULIN RECEPTOR; KIR2DL4 PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; LILRB1 PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR MARKER; TUMOR PROTEIN;

3' UNTRANSLATED REGION; ADULT; ARTICLE; BASE PAIRING; CANCER STAGING; CANCER TISSUE; CELL INFILTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; EXON; FEMALE; GENE EXPRESSION; GENETIC RISK; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; INDEL MUTATION; INTRON; LYMPH NODE; MALE; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; ADOLESCENT; AGED; AMINO ACID SUBSTITUTION; BIOSYNTHESIS; CARCINOMA, NON-SMALL-CELL LUNG; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENETICS; IMMUNOLOGY; LUNG NEOPLASMS; LYMPH NODE METASTASIS; MIDDLE AGED; PATHOLOGY; RISK; TUMOR INVASION; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SUBSTITUTION; ANTIGENS, CD; ANTIGENS, NEOPLASM; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE EXPRESSION PROFILING; GENE FREQUENCY; HLA-G ANTIGENS; HUMANS; INDEL MUTATION; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; RECEPTORS, IMMUNOLOGIC; RECEPTORS, KIR2DL4; RISK; YOUNG ADULT;

EID: 84929044961     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/tan.12561     Document Type: Article

References (48)

1. Pikor A, Ramnarine VR, Lam S, Lam WL. Genetic alterations defining NSCLC subtypes and their therapeutic implications. Lung Cancer 2013: 82: 179-89.
2. Langers I, Renoux VM, Thiry M, Delvenne P, Jacobs N. Natural killer cells: role in local tumor growth and metastasis. Biologics 2012: 6: 73-82.
3. Bruno A, Focaccetti C, Pagani A et al. The proangiogenic phenotype of natural killer cells in patients with non-small cell lung cancer. Neoplasma 2013: 15: 133-42.
4. Esendagli G, Bruderek K, Goldmann T et al. Malignant and non-malignant lung tissue areas are differentially populated by natural killer cells and regulatory T cells in non-small cell lung cancer. Lung Cancer 2008: 59: 32-40.
5. Schneider T, Kumpfler S, Warth A et al. Foxp3+ regulatory T cells and natural killer cells distinctly infiltrate primary tumors and draining lymph nodes in pulmonary adenocarcinoma. J Thorac Oncol 2011: 6: 432-8.
6. - cells and display an impaired capability to kill tumor cells. Cancer 2008: 112: 863-75.
7. Carosella ED, Favier B, Rouas-Freiss N, Moreau P, LeMaoult J. Beyond the increasing complexity of the immunomodulatory HLA-G molecule. Blood 2008: 111: 4862-70.
8. Donadi EA, Castelli EC, Arnaiz-Villena A, Roger M, Rey D, Moreau P. Implications of the polymorphism of HLA-G on its function, regulation, evolution and disease association. Cell Mol Life Sci 2011: 68: 369-95.
9. Urosevic M, Kurrer MO, Kamarashev J et al. Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production. Am J Pathol 2001: 159: 817-24.
10. Yie SM, Yang H, Ye S-r, Li K, Dong D-d, Lin XM. Expression of human leucocyte antigen G (HLA-G) is associated with prognosis in non-small cell lung cancer. Lung Cancer 2007: 58: 267-74.
11. Lin A, Zhu C-C, Chen H-X et al. Clinical relevance and functional implications for human leucocyte antigen-g expression in non-small cell lung cancer. J Cell Mol Med 2010: 14: 2318-29.
12. Rouas-Freiss N, Moreau P, LeMaoult J, Carosella ED. The dual role of HLA-G in cancer. J Immunol Res 2014: 359748. DOI: 10.1155/2014/359748.
13. Rajagopalan S. Endosomal signaling and a novel pathway defined by the natural killer receptor KIR2DL4 (CD158d). Traffic 2010: 11: 1381-90.
14. Rajagopalan S, Long EO. KIR2DL4 (CD158d): an activation receptor for HLA-G. Front Immunol 2012: 3: 1-6.
15. Samaridis J, Colonna M. Cloning of novel immunoglobulin superfamily receptors expressed on human myeloid and lymphoid cells: structure evidence for new stimulatory and inhibitory pathways. Eur J Immunol 1997: 27: 660-5.
16. Cosman D, Fanger N, Borges L et al. A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules. Immunity 1997: 7: 273-82.
17. Colonna M, Navarro F, Bellon T et al. A common inhibitory receptor for major histocompatibility complex class I molecule on human lymphoid and myelomonocytic cells. J Exp Med 1997: 186: 1809-18.
18. Willcox BE, Thomas LM, Bjorkman PJ. Crystal structure of HLA-A2 bound to LIR-1, a host and viral major histocompatibility complex receptor. Nat Immunol 2003: 4: 913-9.
19. Shiroishi M, Tsumoto K, Amano K et al. Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G. Proc Natl Acad Sci U S A 2003: 100: 8856-61.
20. Bellon T, Kitzig F, Sayos J, Lopez-Botet M. Mutational analysis of immunoreceptor tyrosine-based inhibitory motif of the Ig-like transcript 2 (CD85j) leukocyte receptor. J Immunol 2002: 168: 3351-9.
21. Fanger NA, Cosman D, Peterson L, Braddy SC, Maliszewski CR, Borges L. The MHC class I binding proteins LIR-1 and LIR-2 inhibit Fc receptor-mediated signalling in monocytes. Eur J Immunol 1998: 28: 3423-34.
22. Wiśniewski A, Jankowska R, Passowicz-Muszyńska E et al. KIR2DL2/S2 and HLA-C C1C1 genotype is associated with better response to treatment and prolonged survival of patients with non-small cell lung cancer in a Polish Caucasian population. Hum Immunol 2012: 73: 927-31.
23. Wiśniewski A, Bilińska M, Klimczak A et al. Association of the HLA-G gene polymorphism with multiple sclerosis in a Polish population. Int J Immunogenet 2010: 37: 307-11.
24. Gonzalez A, McErlean C, Meenagh A, Shovlin T, Middleton D. Killer cell immunoglobulin-like receptor allele discrimination by high-resolution melting. Hum Immunol 2009: 70: 858-63.
25. Nowak I, Barcz E, Majorczyk E et al. Genetic polymorphism of KIR2DL4 in the Polish population. Tissue Antigens 2015: doi: 10.1111/tan.12544.
26. Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 1987: 8: 138-40.
27. Kaemmerer D, Peter L, Lupp A et al. Comparing of IRS and Her2 as immunohistochemical scoring schemes in gastroenteropancreatic neuroendocrine tumors. Int J Clin Exp Pathol 2012: 5: 187-94.
28. Excoffier L, Slatkin M. Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol 1995: 12: 921-7.
29. Abdallah JM, Goffinet B, Cierco-Ayrolles C, Pérez-Enciso M. Linkage disequilibrium fine mapping of quantitative trait loci: a simulation study. Genet Sel Evol 2003: 2003: 513-32.
30. Rousseeuw PJ, Croux C. Alternatives to the median absolute deviation. J Acoust Soc Am 1993: 88: 1273-83.
31. Nicolae D, Cox NJ, Lester LA et al. Fine mapping and positional candidate studies identify HLA-G as an asthma susceptibility gene on chromosome 6p21. Am J Hum Genet 2005: 76: 349-57.
32. Misra MK, Prakash S, Kapoor R, Pandey SK, Sharma RK, Agrawal S. Association of HLA-G promoter and 14-bp insertion-deletion variants with acute allograft rejection and end-stage renal disease. Tissue Antigens 2013: 82: 317-26.
33. Ober C, Aldrich CL, Chervoneva I et al. Variation in the HLA-G promoter region influences miscarriage rates. Am J Hum Genet 2003: 72: 1425-35.
34. Rousseau P, Le Discorde M, Mouillot G, Marcou C, Carosella ED, Moreau P. The 14 bp deletion-insertion polymorphism in the 3' UT region of the HLA-G gene influences HLA-G mRNA stability. Hum Immunol 2003: 64: 1005-10.
35. Hviid TVF, Hylenius S, Rørbye C, Nielsen LG. HLA-G allelic variants are associated with differences in the HLA-G mRNA isoform profile and HLA-G mRNA levels. Immunogenetics 2003: 55: 63-79.
36. Eskandari-Nasob E, Hashemi M, Hasani SS, Omrani M, Taheri M, Mashhadi MA. Association between HLA-G 3'UTR 14-bp ins/del polymorphism and susceptibility to breast cancer. Cancer Biomark 2013: 13: 253-9.
37. Jeong S, Park S, Park B-W, Park Y, Kwon O-J, Kim H-S. Human leukocyte antigen-G (HLA-G) polymorphism and expression in breast cancer patients. PLoS One 2014: 9: e98284.
38. Silva ID, Muniz YCN, Sousa MCPS et al. HLA-G 3'UTR polymorphisms in high grade and invasive cervico-vaginal cancer. Hum Immunol 2013: 74: 452-8.
39. Goodridge JP, Lathbury LJ, Steiner NK et al. Three common alleles of KIR2DL4 (CD158d) encode constitutively expressed, inducible and secreted receptors in NK cells. Eur J Immunol 2007: 37: 199-211.
40. Le Page MEL, Goodridge JP, John E, Christiansen FT, Witt CS. Killer Ig-like receptor 2DL4 does not mediate NK cell IFN-γ responses to soluble HLA-G preparations. J Immunol 2014: 192: 732-40.
41. Rajagopalan S, Long EO. Comment on "killer Ig-like receptor 2DL4 does not mediate NK cell IFN-γ responses to soluble HLA-G preparations.". J Immunol 2014: 192: 4003.
42. Le Page MEL, Goodridge JP, John E, Christiansen FT, Witt CS. Response to comment on "Killer Ig-like receptor 2DL4 does not mediate NK cell IFN-γ responses to soluble HLA-G preparations.". J Immunol 2014: 192: 4003-4.
43. Shiroishi M, Kuroki K, Rasubala L et al. Structural basis for recognition of the nonclassical molecule HLA-G by the leukocyte Ig-like receptor B2 (LILRB2/LIR2/ILT4/CD85d). Proc Natl Acad Sci U S A 2006: 103: 16412-7.
44. Ponte M, Cantoni C, Biassoni R et al. Inhibitory receptors sensing HLA-G1 molecules in pregnancy: decidua-associated natural killer cells express LIR-1 and CD94/NKG2A and acquire p49, an HLA-G1-specific receptor. Proc Natl Acad Sci U S A 1999: 96: 5674-9.
45. Naji A, Menier C, Morandi F et al. Binding of HLA-G to ITIM-bearing Ig-like transcript 2 receptor suppresses B cell responses. J Immunol 2014: 192: 1536-46.
46. Platonova S, Cherfils-Vicini J, Damotte D et al. Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res 2011: 71: 5412-22.
47. LeMaoult J, Zafaranloo K, Le Danff C, Carosella ED. HLA-G up-regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells. FASEB J 2005: 19: 662-4.
48. Urosevic M, Karamashev J, Burg G, Dummer R. Primary cutaneous CD8+ and CD56+ T-cell lymphomas express HLA-G and killer-cell inhibitory ligand, ILT2. Blood 2004: 103: 1796-8.